Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-03-22 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 10,149,829 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drugs covered by the patent cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-03-22 | 1 | Complaint | or more claims of Vanda’s U.S. Patent No. 10,149,829 (“the ’829 patent”), which, in relevant part, generally…V. THE PATENT-IN-SUIT (U.S. PATENT NO. 10,149,829) … ’829 patent is attached to this Complaint as Exhibit A. 26. The ’829 patent generally…is covered by the ’829 patent, and Vanda has the right to enforce the ’829 patent and sue for infringement…1–14 of the ’829 patent. 39. Teva has infringed the ’829 patent under 35 U.S.C. § | External link to document |
| 2019-05-31 | 15 | Stipulation-General (See Motion List for Stipulation to Extend Time) | Schedule and Claim Construction for U.S. Patent No. 10,149,829 by Vanda Pharmaceuticals Inc.. (Fahnestock… 22 March 2019 1:19-cv-00560 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-06-03 | 16 | SO ORDERED | Schedule and Claim Construction for U.S. Patent No. 10,149,829. Signed by Judge Colm F. Connolly on 6/3… 14 December 2022 1:19-cv-00560 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
